First treatment approved for the management of MCD in Europe

Janssen-Cilag International NV announced today that the European Commission (EC) has approved the use of SYLVANT? (siltuximab) for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative.
SYLVANT? is a monoclonal antibody, a specialised type of protein, that binds selectively to an antigen in the body called interleukin-6 (IL-6). SYLVANT? is administered as an intravenous (IV) infusion once every three weeks and is the first medicine to receive regulatory approval in the EU for the treatment of MCD patients.
Legemiddelselskapet Janssen arbeider for ? m?te dagens store og presserende medisinske behov. Vi driver forskning og utvikling innen f?lgende alvorlige sykdommer: prostatakreft, schizofreni, Alzheimers sykdom, hiv/aids, hepatitt C, tuberkulose, psoriasisartritt og diabetes. V?re medarbeidere drives av ? kunne tilby pasienter nye medisinske l?sninger, produkter og tjenester. Janssen er et verdensomspennende selskap med ansatte i over 50 land og er representert i alle de nordiske landene.
0000Send som e-post
Del denne

Authors

Related posts

Top